BioNTech SE · NASDAQ:BNTX
BioNTech — Q3 2026 Earnings Presentation
27 slides from BioNTech's earnings presentation, Nov 3, 2026
Slide 1: Third Quarter 2026 Financial Results & Corporate Update
Third Quarter 2026 Financial Results & Corporate Update November 3, 2026
Slide 2: This Slide Presentation Includes Forward-Looking Statements
To be updated by Legal This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected r
Slide 3: Progress Highlights, Oncology Execution, Financial Performance
1 Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 2 Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 3 Financial Performance Ramón Zapata, Chief Financial Officer 3
Slide 4: Progress Highlights
1 Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 4
Slide 5: Progress in Q3: Oncology Focus
PROGRESS IN Q3 ONCOLOGY FOCUS IN 1 Late-Stage Acceleration Key late-stage data readouts expected for first wave of oncology assets Gotistobart clinical benefit validated in OS data presented at WCLC 2026 2 Combination Therapy Momentum Pumitamig1 + ADC combination to advance into registrational path
Slide 6: Building a Multi-Product Company Across Tumor Focus Areas by 2030+
Building a Multi-Product Company Across Tumor Focus Areas by 2030+ Targeting 17+ Late-Stage and Pivotal Trial Readouts Informing Multiple Launch Opportunities Expected Data Readouts2 Tumor Type Incidence1 Assets Late-Stage/Pivotal Trials 2026 2027 2028 2029 2030+ 1L NSCLC 400K Pumitamig3 ROSETTA Lun
Slide 7: Oncology Execution
3 Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 7
Slide 8: Tumor-type Focused Strategy to Address Significant Oncology Unmet Needs
Tumor-type Focused Strategy to Address Significant Oncology Unmet Medical Needs Lung Breast Genitourinary Gastrointestinal Gynecologic Additional Tumors Data presented at WCLC and ESMO validate clinical benefit of BioNTech’s product candidates across key tumor types 8
Slide 9: Unique Opportunity to Build a Diversified Lung Cancer Franchise
Unique Opportunity to Build a Diversified Lung Cancer Franchise Pumitamig1 Gotistobart2 Elfetabart Drozuntecan3 Bispecific antibody targeting TME-selective regulatory Novel pan-tumor ADC PD-L1 and VEGF-A with next- T cell-depleting antibody targeting B7H3 with gen IO backbone potential targeting CTL
Slide 10: Broadening BioNTech's Lung Cancer Coverage to Maximize Pipeline Potential
Broadening BioNTech’s Lung Cancer Coverage to Maximize Pipeline Potential NSCLC SCLC Resectable Stage III Unresectable 1L Metastatic 2L+ Metastatic 1L Metastatic 2L+ Metastatic Incidence1 220K 65K 400K 230K 80K 35K Pumitamig2 Gotistobart3 ROSETTA PRESERVE-003 (sq) Pumitamig2 + Pumitamig2 LUNG-202 AD
Slide 11: Gotistobart Phase 3 Data Show Nearly Doubled Median Overall Survival vs SoC
Gotistobart Phase 3 Data Show Nearly Doubled Median Overall Survival vs SoC Median OS was 18.5 months with gotistobart1 vs 10.0 months with docetaxel2 Clinical Evidence Gotistobart Docetaxel Gotistobart reduced the risk of death by (n=45) (n=42) 44% vs. chemotherapy Median OS, mos. 10.0 25.4 month f
Slide 12: Broadening BioNTech's Lung Cancer Coverage to Maximize Pipeline Potential
Broadening BioNTech’s Lung Cancer Coverage to Maximize Pipeline Potential NSCLC SCLC Resectable Stage III Unresectable 1L Metastatic 2L+ Metastatic 1L Metastatic 2L+ Metastatic Incidence1 220K 65K 400K 230K 80K 35K Pumitamig2 Gotistobart3 ROSETTA PRESERVE-003 (sq) Pumitamig2 + Pumitamig2 LUNG-202 AD
Slide 13: Pumitamig + Elfetabart Drozuntecan Demonstrates Early Antitumor Activity Across SCLC Lines
Pumitamig + Elfetabart Drozuntecan Demonstrates Early Antitumor Activity Across SCLC Treatment Lines Pumitamig1 plus ADC elfe-D2 elicits 70.4% ORR in SCLC3 ORR Clinical Evidence Overall (n=71) 70.4% 1L (n=13) 92.3% First global efficacy data for a 60 2L (n=21) 76.2% PD-(L)1xVEGF bsAb + ADC in lung c
Slide 14: Pumitamig + ADC Combination Development Enters Pivotal Phase
Pumitamig + ADC Combination Development Enters Pivotal Phase Compelling Phase 1/2 proof-of-concept data1 for ROSETTA Breast-01: An ongoing Phase 3 trial updated to reflect pumitamig2 + TROP23 ADC support BioNTech’s the evolving 1L TNBC standard of care in collaboration with clinical strategy in 1L T
Slide 15: mRNA Cancer Immunotherapy iNeST and FixVac Portfolio Development Focus
mRNA Cancer Immunotherapy iNeST and FixVac Portfolio Development Focus Autogene cevumeran1 BNT113 BNT116 Adjuvant Adjuvant 1L Multiple settings HPV16+ PD-L1 CPS ≥1 CRC PDAC HNSCC NSCLC Phase 2 Phase 2 Phase 2/3 Phase 1 & 2 Monotherapy + Atezolizumab + mFOLFIRINOX + Pembrolizumab Mono & combo with IO
Slide 16: Multiple Milestones Achieved so Far in 2026
Multiple Milestones Achieved so Far in 2026 Program Trial Readout Phase Indication Status Context Single arm Phase 2 2L+ HER2-expressing endometrial cancer Achieved Trastuzumab pamirtecan3 Chemo naïve HR+ HER2-low breast Met PFS, modest Phase 35 primary analysis Achieved in Q3 cancer improvement Lat
Slide 17: Financial Performance
4 Financial Performance Ramón Zapata, Chief Financial Officer 17
Slide 18: Third Quarter 2026 Financial Results
Third Quarter 2026 Financial Results Revenue from BMS partnership driving quarterly results Q3 2026 Q3 2025 In € millions except per share data1 IFRS Results Adjusted Results2 IFRS Results Adjusted Results2 Revenues 1,289 1,289 1,519 1,519 Cost of sales (103) (92) (148) (148) Research and developmen
Slide 19: Q3 Year-to-Date 2026 Financial Results at a Glance
Q3 Year-to-Date 2026 Financial Results at a Glance1 Continued Focus on R&D Priority Programs Revenues € 1,513 MILLION vs. €1,963 million year-to-date 2025 vs. €1,514 million year-to-date 2025 Adjusted R&D Expenses² € 1,583 MILLION IFRS R&D Expenses: €1,856 million vs. €1,600 million year-to-date 202
Slide 20: Updated Full Year 2026 Financial Guidance
Updated Full Year 2026 Financial Guidance1 FY 2026 non-IFRS Guidance Current Prior In € millions Nov. 3, 2026 Aug. 4, 2026 Revenues 1,700 – 1,900 1,600 – 1,900 Adjusted R&D Expense Unchanged 2,000 – 2,300 Adjusted SG&A Expense Unchanged 700 - 800 1. Excludes risks that are not yet known and/or quant
Slide 21: Thank you
Thank you
Slide 22: Appendix
__. Appendix BIONT=Cr
Slide 23: Reconciliation of IFRS to Adjusted Results – Q3 2026 & 2025
Reconciliation of IFRS to Adjusted Results – Q3 2026 & 2025 Financial Results Q3 2026 Q3 2025 In € millions IFRS Non-IFRS Adjusted IFRS Non-IFRS Adjusted except per share data1 Results Adjustments Results2 Results Adjustments Results2 Revenues 1,289 – 1,289 1,519 – 1,519 Cost of sales (103) 11 (92)
Slide 24: Reconciliation of IFRS to Adjusted Results – YTD 2026 & 2025
Reconciliation of IFRS to Adjusted Results – YTD 2026 & 2025 Financial Results Year-to-date 2026 Year-to-date 2025 In € millions IFRS Non-IFRS Adjusted IFRS Non-IFRS Adjusted except per share data1 Results Adjustments Results2 Results Adjustments Results2 Revenues 1,513 – 1,513 1,963 – 1,963 Cost of
Slide 25: BioNTech's Oncology Pipeline
BioNTech’s Oncology Pipeline Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 BNT116 BNT317 Pumitamig1 Pumitamig1 + Autogene Pumitamig1 Tenumomeran/ Elfetabart Pumitamig1 Adv. NSCLC Multiple solid tumors Adv. RCC Beruzatatug cevumeran2 2L ES-SCLC8 Raplemomeran Drozuntecan3 1L adv./met.TNBC8 pelitecan5 Ad
Slide 26: BioNTech's Infectious Diseases Pipeline
BioNTech’s Infectious Diseases Pipeline Phase 1 Phase 1/2 Phase 2 Commercial BNT1631 BNT1644 BNT1665 BNT1622,3 HSV Tuberculosis Mpox COVID-19 BNT351 HIV BNT1684 HIV Antibody mRNA Partnered with: 1. University of Pennsylvania; 2. Pfizer; 3. Fosun Pharma; 4. Funded by the Gates Foundation; 5. Funded b
Slide 27: Abbreviation Directory
Abbreviation Directory nL nth line FY Fiscal year OS Overall survival AACR American Association for Cancer Research G7 markets Canada, France, Germany, Italy, Japan, GB, USA PDAC Pancreatic ductal adenocarcinoma ADC Antibody-drug conjugate GB Great Britain PD-(L)1 Programmed cell death protein (liga